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ABSTRACT
Objective To evaluate the genetic ﬁndings,
demographic features and clinical presentation of tumour
necrosis factor receptor-associated autoinﬂammatory
syndrome (TRAPS) in patients from the Eurofever/
EUROTRAPS international registry.
Methods A web-based registry collected retrospective
data on patients with TNFRSF1A sequence variants and
inﬂammatory symptoms. Participating hospitals included
paediatric rheumatology centres and adult centres with a
speciﬁc interest in autoinﬂammatory diseases. Cases
were independently validated by experts in the disease.
Results Complete information on 158 validated
patients was available. The most common TNFRSF1A
variant was R92Q (34% of cases), followed by T50M
(10%). Cysteine residues were disrupted in 27% of
cases, accounting for 39% of sequence variants.
A family history was present in 19% of patients with
R92Q and 64% of those with other variants. The median
age at which symptoms began was 4.3 years but 9.1% of
patients presented after 30 years of age. Attacks were
recurrent in 88% and the commonest features associated
with the pathogenic variants were fever (88%), limb pain
(85%), abdominal pain (74%), rash (63%) and eye
manifestations (45%). Disease associated with R92Q
presented slightly later at a median of 5.7 years with
signiﬁcantly less rash or eye signs and more headaches.
Children were more likely than adults to present with
lymphadenopathy, periorbital oedema and abdominal
pains. AA amyloidosis has developed in 16 (10%)
patients at a median age of 43 years.
Conclusions In this, the largest reported case series to
date, the genetic heterogeneity of TRAPS is accompanied
by a variable phenotype at presentation. Patients had a
median 70 symptomatic days a year, with fever, limb and
abdominal pain and rash the commonest symptoms.
Overall, there is little evidence of a signiﬁcant effect of
age or genotype on disease features at presentation.
INTRODUCTION
The tumour necrosis factor receptor-associated
periodic fever syndrome (TRAPS) was ﬁrst
described as familial Hibernian fever in 19821 but
was renamed after the discovery that it is associated
with mutations in the gene for tumour necrosis
factor receptor superfamily member 1A
(TNFRSF1A), on chromosome 12.2 3 It is now
recognised as one of the hereditary recurrent fever
syndromes, a group of autoinﬂammatory diseases
caused by inappropriate activity of the innate
immune system.4 5 Most sequence variants (SVs)
underlying TRAPS lie within exons 2 to 4, and
there appears to be over-representation of missense
substitutions which disrupt structurally important
cysteine–cysteine disulﬁde bonds in the extracellu-
lar domain (Infevers database: http://fmf.igh.cnrs.fr/
ISSAID/infevers/).6–8 The mechanism(s) by which
heterozygous TNFRSF1A SVs cause TRAPS remain
(s) unclear and probably differ(s) between var-
iants.9–13 The two commonest TNFRSF1A variants,
P46L and R92Q, which are only associated with
symptoms in a minority of people, are present in
about 10% of West Africans and 2% of Caucasians,
respectively.14 There is haplotype evidence of a
common founder in R92Q5 and it may be a minor
susceptibility factor for development of multiple
sclerosis.15 The vast majority of carriers of these
two variants are entirely well, and how they cause
inﬂammatory disease in a minority remains
obscure.
TRAPS is a very rare disease with an estimated
prevalence of about one per million.16 It has been
more frequently reported in Caucasians but
whether this reﬂects true increased incidence or
ascertainment bias is uncertain. TRAPS is a far less
distinct disease entity than familial Mediterranean
fever; attacks can be discrete or near continuous
and are often prolonged, lasting several weeks and
accompanied by a variety of features, including
fever, abdominal pain, rash, eye manifestations,
headache, pleuritic pain and lymphadenopathy.5
Symptoms are almost universally accompanied by a
marked acute phase response and leucocytosis.
Diagnosis relies on clinical suspicion supported
by genetic testing, but this has been severely ham-
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pered by the absence of any large-scale description of disease
manifestations and by the absence of any validated diagnostic
criteria.17 To further complicate the diagnosis, it is not known
whether clinical features vary with age and thus if the disease
presents differently in children. It is also unknown whether fea-
tures at presentation predict the subsequent course of the
disease and complications, or whether there is genotype-–
phenotype correlation in relation to clinical presentation and/or
severity.
The combined European Union-funded projects of Eurofever
and EUROTRAPS sought to answer these questions by collect-
ing data on large numbers of patients in a common registry.18
We here describe the clinical manifestations at presentation in
158 patients, of whom 53 were children (aged <18 at data col-
lection) and 105 adults.
PATIENTS AND METHODS
The data analysed in this study were extracted from the
Eurofever/EUROTRAPS registry (EAHC project numbers:
2007332 and 200923), which has been enrolling since
November 2009.18 19 Ethical committee approval for entering
patients in the registry and informed consent or assent was
obtained in the participating countries according to local regula-
tory requirements.
Inclusion criteria were symptomatic inﬂammatory disease
associated with a TNFRSF1A variant. Demographic information,
clinical manifestations and laboratory ﬁndings at presentation
were collected. Information about molecular genetic analysis
was also collected, including the sequence variants found
(Infevers database, http://fmf.igh.cnrs.fr/ISSAID/infevers/).
Clinical details were sought about the features at disease onset
rather than at diagnosis and included (i) characteristics of fever
episodes (duration, frequency, triggers, etc), (ii) presence and
frequency (always or often/sometimes) of clinical manifestations.
All completed cases were anonymously and independently vali-
dated by at least one expert in the disease (HJL, PW, MG) in
order to conﬁrm the diagnosis. This analysis includes all cases
validated before June 2012.
Statistics
Frequencies and percentages were used as descriptive statistics
for categorical variables. To describe numerical variables median
and range were used. Differences among groups were assessed
by Mann–Whitney U test or Kruskal–Wallis test when evaluating
continuous variables and by χ2 tests for discrete variables. Post
hoc analysis between groups was performed by Mann–Whitney
U test or χ2 test; no adjustments for multiple comparisons were
performed. In order to analyse the clinical phenotype of the
patients according to the type of gene variants, we divided the
patients into three subgroups: (A) patients carrying cysteine or
T50M variants, (B) patients with other variants and (C) patients
with the low-penetrance variants R92Q and P46L.
RESULTS
Demographic data
In June 2012, 224 patients with TRAPS were available in the
registry. Of these, 59 patients were excluded as only baseline
demographic data without clinical information were available,
and seven patients were excluded at the validation stage. None
of these had mutations detected in TNFRSF1A, four had no spe-
ciﬁc symptoms, one responded well to broad-spectrum immuno-
suppressant agents with extremely short attacks of systemic
inﬂammation, one had recurrent pericarditis and the ﬁnal
patient had a new NLRP3 mutation and non-speciﬁc mild
symptoms. A total of 158 analysed patients were enrolled by 18
centres in 11 countries. All patients but one were enrolled by
European centres: UK (64 patients), Italy (38), France (17),
Germany (16), Spain (8), Netherlands (6), Ireland (4), Greece
(2), Slovenia (1) and Turkey (1). One patient born in the UK
was enrolled in Australia. Eight patients had immigrated to the
country of the referral centre and originated from Portugal,
Slovakia, Canada, the Congo, Nigeria, Mauritius, Kuwait and
Iraq. Most of the patients (147, 93%) were European
Caucasians. Four were Arab originating from the Middle East or
North Africa; three were sub-Saharan African and two South
Asians. Two patients had a mixed origin: Caucasian/Asian and
Caucasian/African, respectively.
Demographic details are summarised in table 1. The median
age at enrolment was 33.8 years (range 3–77). The majority of
the patients were adults (105, 66%). Fifty-three patients (34%)
were children or adolescents aged <18 years. Across the whole
cohort the median age at symptom onset was 4.3 years (range
0.2–63); it was 4 years (range 0–49) in patients with a SV and a
median of 5.7 years (range 0–53) in patients with R92Q (not
signiﬁcant). Development of symptoms after the age of 30 years
was seen in 9.1% of patients with no difference between those
with low-penetrant variants and those carrying other SVs.
Median disease duration at enrolment was 15.6 years, in the
children it was 6.6 years and in adults 27.7 years. The median
age at diagnosis with TRAPS for the whole group was
25.9 years; children were diagnosed at 6.2 years; whereas diag-
nosis in adults was at a median of 37.9 years, reﬂecting a
median diagnostic delay of 10.3 years, which was almost 10
times higher than in the study paediatric patients.
Genotypic characterisation
All patients had SVs in TNFRSF1A. Sequencing of the whole
gene was performed in nine patients (6%) and a search for a
single mutation was performed in ﬁve patients (3%). In the
majority of patients (134, 85%) selected exons, mainly from 1
to 4, had been analysed. In total 46 variants were found, the
complete list is reported in table 2. The vast majority of the
patients were heterozygous for missense mutations involving
exon 2 (29 patients), exon 3 (59 patients) and exon 4 (64
patients). Five patients carried variants in non-coding intronic
regions of the gene. One patient displayed a large deletion in
exon 6. Only 19 variants (41.3%) were identiﬁed in more than
one unrelated individual.
Table 1 Demographic characteristics of patients with TRAPS at
the time of enrolment
Characteristics
Whole TRAPS
population
Paediatric
patients
Adult
patients
Number of patients 158 53 105
Male:female 78:80 31:22 47:58
Age at onset (years) 4.3 (0–63) 1.5 (0–13) 8 (0–63)
Age at diagnosis (years) 25.9 (0–77) 6.2 (0–15) 37.9 (1–77)
Age at enrolment (years) 33.8 (3–77) 11.2 (3–18) 42.3 (19–77)
Diagnostic delay (years) 10.3 (0–77) 2.7 (0–14) 22.4 (0–77)
Disease duration (years) 15.6 (1–77) 6.6 (1–17) 27.7 (1–77)
Disease onset at
<18 years, n (%)
123 (78) 53 70 (67)
Disease onset aged
≥18 years, n (%)
35 (22) – 35 (33)
Results are shown as median (range) unless stated otherwise.
Lachmann HJ, et al. Ann Rheum Dis 2014;73:2160–2167. doi:10.1136/annrheumdis-2013-204184 2161
Clinical and epidemiological research
UniversitÃƒÂƒÃ‚ÂƒÃƒÂ‚Ã‚ÂƒÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â  degli Studi di Milano. Protected by copyright.
 o
n
 August 27, 2019 at
http://ard.bmj.com/
Ann R
heum
 D
is: first published as 10.1136/annrheum
dis-2013-204184 on 21 August 2013. Downloaded from
 
The distribution of the genotype according to age and disease
onset is shown in table 3. T50M was the single commonest
variant, found in 16 patients including ﬁve unrelated kindreds
from ﬁve different countries. Eighteen different variants involv-
ing cysteine residues were found in 42 patients. In 30 patients
(19%) other missense variants previously reported to be
associated with a TRAPS phenotype were seen (Infevers: http://
fmf.igh.cnrs.fr/ISSAID/infevers/); another 12 patients carried
variants for which the association with the clinical phenotype
had not previously been considered certain. The low-penetrant
variants, R92Q and P46L, were found in 54 and ﬁve patients,
respectively. Four of the P46L cases also had sequencing of
Table 2 The TNFRSF1A variants in the 158 patients
Variant (protein variant) Location Number of cases (%) Ethnicity
D12E (p.Asp41Glu) Exon 2 3 (2) Caucasian
H22Q (p.His51Gln) 2 (1) Caucasian
H22R (p.His51Arg) 3 (2) Caucasian
C29F (p.Cys58Phe) 1 (0.5) Caucasian
C29Y (p.Cys58Tyr) 1 (0.5) Asian
C30F (p.Cys59Phe) 1 (0.5) Caucasian
C30R (p.Cys59Arg) 4 (3) Caucasian
C30Y (p.Cys59Tyr) 1 (0.5) Caucasian
C33G (p.Cys62Gly) 1 (0.5) Arab
C33Y (p.Cys62Tyr) 12 (8) Caucasian
c.193-14G>A Intron 2 1 (0.5) Caucasian
c.194-15C>T 1 (0.5) Caucasian
T37I (p.Thr66Ile) Exon 3 2 (1) Arab
1 (0.5) Caucasian
Y38S (c.200A>C) 1 (0.5) Caucasian
L39F (p.Leu68Phe) 4 (3) Caucasian
D42DEL (p.Asp71del) 1 (0.5) Caucasian
C43G (c214T>G) 3 (2) Caucasian
C43R (p.Cys72Arg) 1 (0.5) Caucasian
C43S (p.Cys72Ser) 1 (0.5) Caucasian
C43Y (p.Cys72Tyr) 5 (3) Arab, Sub-Saharan African×2, Caucasian×2
P46L (p.Pro75Leu) Caucasian
Caucasian×15, African×1
T50K (p.Thr79Lys) 2 (1) Caucasian Caucasian×3, Arab×1
T50M (p.Thr79Met) 16 (10) Caucasian
Caucasian
C52Y (p.Cys81Tyr) 5 (3) Caucasian
C55Y (p.Cys84Tyr) 4 (3) Caucasian
Caucasian
S59P (p.Ser88Pro) 1 (0.5) Caucasian
F60L (p.Phe89Leu) 2 (1) Caucasian
T61N (p.Thr90Asn) 2 (1)
N65I (p.Asn94Ile) 2 (1) Caucasian
H66L (p.His95Leu) 1 (0.5) Caucasian
L67P (p.Leu96Pro) 1 (0.5)
H69fs (p.His98_Cys99delinsArg) 1 (0.5)
C73R (p.Cys102Arg)
C73W (p.Cys102Trp) 1 (0.5)
2 (1)
C88Y (p.Cys117Tyr) Exon 4 1 (0.5) Caucasian
R92P (p.Arg121Pro) 1 (0.5) Caucasian
R92Q (p.Arg121Gln) 54 (34) Caucasian
V95M (p.Val124Met) 2 (1) Caucasian
C96Y (p.Cys125Tyr) 1 (0.5) Caucasian
Y103_R104DEL (p.Tyr132_Arg133del) 1 (0.5) Caucasian
E109A (p.Glu138Ala)
C114W (p.Cys143Trp 2 (1) Caucasian
N116S (p.Asn145Ser) 1 (0.5) Caucasian
1 (0.5) Caucasian
c.472+6C>T Intron 4 2 (1) Caucasian
L167_G175del (c.586_612del127 Exon 6 1 (0.5) Asian
Intronic substitution c626-32G>T Intron 6 1 (0.5) Caucasian
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additional fever genes; MEFV in three cases, and MEFV, NLRP3
and MVK in the other with no variants found. Of the patients
carrying R92Q, 24 patients underwent additional sequencing:
MEFV in 22 cases, MVK in 11 and NLRP3 in two. Two patients
were found to carry MEFV variants, one case each of E148Q
and R121Q.
In adult patients a SV involving T50M or a cysteine residue
was seen in 26 (51%) of those with disease onset in childhood
and eight patients (22.9%) with an adult onset (p<0.001).
Conversely, in the adults in this study the prevalence of the low-
penetrant variants, R92Q and P46L, was twice as high in those
with an adult onset (49%) compared with those with a paediat-
ric onset (21%) (p<0.001). In paediatric patients the distribu-
tion of mutation types was similar to that seen in adult-onset
TRAPS (table 3). A family history of TRAPS was reported by 11
(19%) patients with the lower-penetrance R92Q variant. In
patients with other SVs 64% had a suggestive family history,
and this was exactly the same in the subgroup of T50M and var-
iants involving a cysteine residue.
Clinical features at presentation
At presentation 139 patients (88%) reported that their symp-
toms occurred in recurrent episodes and only 11 (7%) had
continuous symptoms (three C33Y, two C73W, ﬁve R92Q, one
P46L) (table 4). In the remaining eight patients disease was con-
tinuous with episodic ﬂares. The disease burden was high with
an average of 70 symptomatic days a year. Median attack dur-
ation was 10.8 days for the whole cohort with no signiﬁcant dif-
ferences in the duration or number of attacks between the
paediatric and adult populations. There was considerable vari-
ation in attack duration with a third of attacks lasting less than a
week, shorter attacks were more frequent in patients with low-
penetrance SVs, accounting for 40% compared with 26% in
patients with mutations affecting T50M or cysteine residues
(p<0.05) (ﬁgure 1). Only 12% of patients reported regular pre-
dictable attacks, but these were commoner in paediatric patients
than in adults (26.4% and 4.8% respectively, p<0.05). Just over
a quarter of patients (40 cases) could identify triggers for their
attacks. The commonest reported triggers were emotional stress
(21 patients); menstrual cycle (17); fatigue (10); infections (9);
exercise (7) and vaccinations (6). There were no signiﬁcant dif-
ferences between the incidence and type of triggers in children
and adults except for the entirely explicable ﬁndings that vaccin-
ation and infections were reported more commonly in children
(who are more exposed to them) and the menstrual cycle in
females after menarche. A fever of >38°C was reported by
Table 3 Major groups of genetic variants in the different age groups of patients with TRAPS
Whole TRAPS population Paediatric patients Adults with paediatric onset Adults with adult onset
Number (%) Number (%) Number (%) Number (%)
Sequence variants involving a cysteine residue or T50M 58 (37) 14 (26) 26 (37) 8 (23)
Other sequence variants 41 (26) 12 (23) 19 (27) 10 (29)
R92Q or P46L 59 (37) 27 (51) 15 (21) 17 (49)
Total number of patients (% of total) 158 (100) 53 (34) 70 (44) 35 (22)
Table 4 Characteristics of fever episodes according to the age and disease onset
Whole TRAPS population Paediatric patients Adults with paediatric onset Adults with adult onset
(n=158) (n=53) (n=70) (n=35)
Number of patients Number (%) Number (%) Number (%) Number (%)
Disease course
Recurrent* 139 (88) 48 (91) 57 (81) 34 (97)
Continuous† 11 (7) 4 (8) 6 (9) 1 (3)
Continuous with flares 8 (5) 1 (2) 7 (10) 0
Characteristics of the disease episodes
Duration
>14 days 32 (25) 10 (24) 14 (24) 8 (27)
7–14 days 55 (43) 18 (43) 26 (46) 11 (37)
<7 days 42 (33) 14 (33) 17 (29) 11 (37)
Mean duration (days) 10.8 10.7 10.9 10.9
Mean number of episodes/year 7.7 7.7 7.6 6.9
Fever (>38°C) 132 (84) 48 (91) 56 (80) 28 (80)
Low-grade fever (<38°C) 57 (36) 16 (30) 27 (39) 14 (40)
Rigours/chills at fever onset 48 (30) 18 (34) 25 (36) 5 (14)
Pattern of attacks
Irregular 91 (58) 32 (60) 39 (56) 20 (57)
Regular 19 (12) 14 (26) 4 (6) 1 (3)
Seasonal changes 4 (2.5) 1 (3) 3 (4) 0
Triggers 40 (25) 15 (28) 19 (27) 6 (17)
*Recurrent manifestations with disease-free intervals.
†Continuous/subchronic manifestations with possible episodic flares.
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83.5% of patients with no difference between adult and paediat-
ric cases, and rigours occurred in 30%.
The most common symptoms accompanying episodes are
reported in table 5. The dominant classes of symptoms: fever,
limb pain, abdominal pain and rash were seen in 88%, 85%,
74% and 63% of patients with clear-cut variants; and 94%,
79%, 64% and 30% of patients with the R92Q variant, respect-
ively. Periorbital oedema, a pathognomic feature of TRAPS was
seen in 20% of the whole cohort. Comparison of the different
variant groups ((A) variants affecting cysteine residues and
T50M, (C) the low-penetrance variants R92Q and P46L and
(B) all other SVs) showed remarkably few differences which
reached signiﬁcance. Patients in groups A and B were more
likely than patients with R92Q to have a rash (63% vs 30%
(p<0.001)) and eye symptoms (45% vs 26% (p<0.05)).
Patients with R92Q had signiﬁcantly more headaches (40% vs
13% (p<0.001) and a non-signiﬁcant trend towards more oro-
pharyngeal symptoms (30% vs 19%) (table 5).
A comparison of patients who presented in childhood (the 53
paediatric patients and 70 adult patients with childhood onset)
with the 30 adult patients (with ﬁrst symptoms after the age of
18 years) showed that the only signiﬁcant differences were cer-
vical lymphadenopathy, which was present in 31% of attacks
presenting in childhood and 9% of adults; periorbital oedema
and abdominal pain were also commoner in childhood presenta-
tion occurring in 24% and 74%, respectively (p<0.05). Only
chest pain with attacks was signiﬁcantly more frequent in adult
presentation, occurring in 54% compared with 20% in child-
hood (p<0.05); in general, chest pain was most frequent in
patients with T50M (6/16 cases), although they reported
neither pericarditis nor pleurisy (table 5).
AA amyloidosis occurred in 16 cases (10%) at a median age
of 43 years (range 20–77). This group included seven cysteine
variants (44%), two T50M (13%) and no patients with R92Q.
Patients who developed AA amyloidosis had signiﬁcantly longer
disease duration than those who did not (39 vs 19.4 years
(p<0.001) and 13 of the 16 cases had their ﬁrst symptoms in
childhood.
DISCUSSION
This is the largest reported series of patients with symptoms and
conﬁrmed variants in the TNFRSF1A gene and shows the
strength of international cooperation in the study of an
extremely uncommon condition which can present to a wide
variety of specialties, and to both paediatric and adult services.
The diagnosis of very rare diseases relies on a high ‘index of sus-
picion’ followed by speciﬁc testing. In diseases where the diag-
nostic test is both expensive and of limited availability we hope
that deﬁnition of what constitutes a ‘target group’ will facilitate
early recognition of probable cases and appropriate use of
limited resources. These results show that TRAPS is a pleio-
morphic condition characterised by attacks of fever in >83%
accompanied by symptoms including diffuse limb pain, abdom-
inal pain and rash. In many respects our data conﬁrm the case
descriptions from earlier publications,5 20–24 but it is also
important to recognise that by no means all patients fall into a
tightly circumscribed phenotype. In particular, despite its auto-
somal dominant nature, a family history of TRAPS is reported
by fewer than two-thirds of patients, and symptoms begin after
the age of 18 years in 22%. In addition, although the average
disease attack lasts for >10 days, 30% last for less than a week,
and hence brief febrile episodes cannot be used to exclude the
diagnosis.
The size of this series allows, for the ﬁrst time, an exploration
of genotype–phenotype associations and also of the effect of
patient age on disease features at presentation. Mutations affect-
ing cysteine residues and the T50M variant were among the ﬁrst
identiﬁed in TRAPS.25 They have been widely regarded as asso-
ciated with higher penetrance, a more severe disease phenotype
and a high risk of AA amyloidosis. Our series includes 58 such
patients and has found that a family history was no commoner
in them than in other non-R92Q P46L sequence variants, but
that their disease was more likely to persist into adulthood. No
particular pattern of clinical features was commoner in patients
with these sequence variants, and they did not appear to be
over-represented among patients who developed AA
amyloidosis.
Analysis of patients with the R92Q variant showed that these
patients had a slightly different disease phenotype, with a lower
proportion of familial disease, more headaches and fewer rash
and eye manifestations. The lower percentage in adult patients
with paediatric onset compared with both the children and
patients who presented in adulthood, suggests that manifestation
of R92Q-associated disease tends to be either as febrile attacks
in children, which ameliorate as they mature, or as a genuinely
later-onset disease. Both these clinical scenarios are consistent
with a milder phenotype,26 and certainly no patients with
R92Q have developed the most feared complication of TRAPS,
AA amyloidosis.27 The role of low-penetrance variants in
TRAPS disease aetiology has long been contentious. It remains
possible that TNFRSF1A R92Q is simply acting as a modiﬁer in
patients with other, as yet, unidentiﬁed causes of an inﬂamma-
tory phenotype. In this series 24 (44%) patients had undergone
sequencing of at least one other fever gene with only two cases
found to carry the equally controversial MEFV sequence var-
iants E148Q and R121Q, suggesting that we were not missing
other common clear-cut inherited autoinﬂammatory conditions.
The very high proportion of patients with R92Q in this series
supports the view that R92Q-associated disease is a genuine
phenomenon, although one that affects only a minority of car-
riers. Our results are more equivocal for P46L. We recruited
only ﬁve patients; two of these were Caucasian but the other
three were from populations with a known high gene carriage
rate, one Arab and two of West African origin. It remains pos-
sible that their genetic ﬁndings are entirely incidental to their
symptoms. Next-generation sequencing may help to clarify the
signiﬁcance of such common relatively low-penetrance variants.
Figure 1 Duration of the episodes according to the major groups of
genetic variants in patients with TRAPS expressed as a percentage of
attacks. Group A patients carry a sequence variant involving a cysteine
residue or T50M; group B patients carry other sequence variants; group
C patients carry R92Q or P46L.
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Table 5 Clinical manifestations reported in patients with TRAPS at disease presentation by age and mutation group
Whole TRAPS
population
Pediatric
patients (A)
Adults with
pediatric onset (B)
Adults with
adult onset (C)
Cysteine or
T50M (D)
Other
mutations (E)
Low-penetrance
mutations (F)
(n=158) (n=53) (n=70) (n=35) (n=58) (n=39) (n=59)
Number of patients Number (%) Number (%) Number (%) Number (%) p Value* Number (%) Number (%) Number (%) p Value*
Mucocutaneous
Exudative pharyngitis 5 (3) 3 (6) 1 (1.5) 1 (3) NS 2 (3) 0 3 (5) NS
Erythematous pharyngitis 28 (18) 12 (23) 11 (16) 5 (14) NS 7 (12) 7 (18) 14 (24) NS
Aphthous stomatitis 15 (9.5) 7 (13) 4 (6) 4 (11) NS 3 (5) 4 (10) 8 (14) NS
Palpable purpura 1 (0.5) 1 (2) 0 0 NS 0 0 1 (2) NS
Maculopapular rash 41 (26) 17 (32) 17 (24) 7 (20) NS 14 (24) 15 (38) 12 (20) NS
Urticarial rash 39 (25) 12 (23) 20 (29) 7 (20) NS 15 (26) 11 (28) 13 (22) NS
Migratory rash 28 (18) 9 (17) 16 (23) 3 (9) NS 16 (28)* 7 (18) 5 (8) 0.01
Erysipelas-like erythema 7 (4) 1 (2) 6 (9) 0 0.04 6 (10)† 0 1 (2) 0.03
Localised erythema 4 (2.5) 1 (2) 2 (3) 1 (3) NS 0 2 (5) 2 (3) NS
Generalised erythema 3 (2) 1 (2) 1 (1.5) 1 (3) NS 0 1 (3) 2 (3) NS
Pseudo-folliculitis 3 (2) 1 (2) 1 (1.5) 1 (3) NS 0 1 (3) 2 (3) NS
Musculoskeletal
Arthralgia 101 (64) 34 (64) 48 (69) 19 (54) NS 34 (58) 28 (72) 39 (66) NS
Myalgia 111 (70) 36 (68) 53 (76) 22 (63) NS 43 (74) 29 (74) 39 (66) NS
Myositis 3 (1.5) 1 (2) 2 (3) 0 NS 3 (5) 0 0 0.04
Fasciitis 6 (4) 0* 5 (7) 1 (3) 0.04 4 (7) 1 (3) 1 (2) NS
Bone pain 6 (4) 2 (4) 2 (3) 2 (6) NS 2 (3) 0 4 (7) NS
Monoarthritis 9 (6) 4 (8) 2 (3) 2 (4) NS 4 (7) 1 (3) 4 (7) NS
Oligoarthritis 15 (9.5) 2 (4) 9 (13) 4 (11) NS 8 (14) 2 (5) 5 (8) NS
Polyarthritis 2 (4) 1 (1.2) 2 (3) 5 (14) 0.04 2 (3) 1 (3) 1 (2) NS
Ocular
Periorbital oedema 32 (20) 8 (15) 21 (30) 2 (4) NS 14 (24) 8 (20) 10 (17) NS
Periorbital pain 20 (13) 6 (11) 10 (14) 4 (11) NS 12 (21)* 2 (5) 6 (10) 0.03
Conjunctivitis 35 (22) 6 (11) 23 (33) 6 (17) NS 18 (31)† 17 (44)‡ 10 (17) 0.02
Gastrointestinal
Vomiting 28 (18) 13 (25) 9 (13) 6 (17) NS 6 (10) 7 (18) 15 (26) NS
Abdominal pain 110 (70) 38 (72) 53 (76)‡ 19 (54) 0.05 47 (81) 27 (69) 36 (61) NS
Constipation 21 (13) 2 (3.8)*† 12 (17) 7 (20) 0.01 13 (22)* 2 (5) 6 (10) 0.02
Diarrhoea 28 (18) 12 (23) 10 (14) 6 (17) NS 11 (19) 7 (18) 10 (17) NS
GI bleeding 3 (1.5) 0 1 (1.5) 2 (6) NS 3 (5.1) 0 1 (2) NS
Aseptic peritonitis 10 (6) 0 9 (13) 1 (3) 0.01 5 (9) 2 (5) 3 (5) NS
Lymphoid organs
Generalised enlargement 12 (8) 6 (11) 5 (7) 1 (3) NS 5 (9) 3 (8) 4 (7) NS
Enlarged cervical lymph
nodes
41 (26) 23 (43) 15 (21) 2 (4) 0.01 16 (28) 10 (26) 15 (25) NS
Inguinal lymphadenopathy 2 (1) 1 (2) 0 1 (3) NS 0 0 2 (3) NS
Lymph node pain 21 (13) 10 (19) 10 (14) 1 (3) NS 9 (16) 5 (13) 7 (12) NS
Hepatomegaly 9 (6) 5 (9) 4 (6) 0 NS 4 (7) 3 (8) 2 (3) NS
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Although disease features seem to be similar in children and
adults at presentation, there is a suggestion that some clinical
manifestations, such as serositis, arthritis and constipation might
be related to disease in adulthood (table 5).
Our study has a number of obvious limitations. Although
multiple centres were involved most of these were specialist,
and recruitment was unequally distributed, introducing a risk of
geographical or centre-speciﬁc bias. The marked disparity in the
number of patients from each country demonstrates this, since it
seems very unlikely that TRAPS is several-fold more common in
the UK and Italy. In addition this is a ‘Eurocentric’ cohort.
TRAPS has been reported to occur in a wide spectrum of popu-
lations and given the large number of variants reported, the
high rate of family-speciﬁc variants (58% occurred in only one
individual or family in this cohort) and absence of any postu-
lated speciﬁc selective advantage in Europe, it seems likely that
TRAPS occurs throughout the world and that variations
between populations reﬂect ascertainment bias due a combin-
ation of lack of awareness of a rare condition and difﬁculties in
accessing or ﬁnancing genetic testing. Using rather limited
ethnic groups to deﬁne TRAPS disease has potential drawbacks.
The most obvious of these arises if rash is made a central com-
ponent of the diagnostic criteria, particularly as the rashes seen
in TRAPS are often evanescent and macular, therefore much
more prominent on paler-skinned individuals. We also have
some concerns that there may be bias in the selection of patients
entered into this study favouring patients with more severe
disease and perhaps also patients with systemic symptoms as iso-
lated rash or abdominal pain may be managed without consider-
ing the diagnosis. This may be most evident in patients with the
lower-penetrant variants where only patients with particularly
severe features have been referred to specialist centres and our
data may therefore reﬂect only the most severe end of the spec-
trum of R92Q-associated disease. In addition, two-thirds of the
study group were adults at recruitment and their recollection of
their disease at presentation might have been imprecise, espe-
cially in older adults recollecting childhood illness many
decades earlier.26
Finally, although we report disease features at presentation
here, other aims of the registry are to follow-up patients over
the long term. This should allow description of treatment
responses and long-term outcomes (both medical and socio-
economic), and also the opportunity to identify prognostic
factors and raise disease awareness.
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